Jessica K Altman

10PUBLICATIONS
98CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 25, 2025
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Eunice S Wang, Pau Montesinos, James Foran

|Feb 22, 2024
Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.

Juehua Gao, Lucas Santana-Santos, Lucy Fu

|Oct 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Jessica K Altman, Tsila Zuckerman, Jamie Koprivnikar

|Sep 27, 2023
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.

Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi

|Jun 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

Keith W Pratz, Mohamad Cherry, Jessica K Altman

|Jul 18, 2022
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, Alexander E Perl, Joseph Maly

Pageof 2

Frequent Collaborators

3 joint publications

Keith W Pratz

2 joint publications

Gail Roboz

2 joint publications

Mark Litzow

2 joint publications

Naval Daver